UChicago Medicine
G

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges in Lymphoma Management

By UChicago Medicine FEATURING Girish Venkataraman, Anamarija Perry, Kirk Cahill, Aibek Akmatbekov, Leo Wu
By UChicago Medicine FEATURING Girish Venkataraman, Anamarija Perry, Kirk Cahill, Aibek Akmatbekov, Leo Wu
214 views
July 18, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Related Content

AUTOPLAY
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

16:34
Jennifer Amengual

Top 5 Lymphoma Abstracts From ASH

15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
28:11
Total Health

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Feat. M. Rotta
25:22
Integrity CE

Treatment Updates and Management of Non-Hodgkin Lymphomas

Feat. D. Wallace, M. Cortese
14:47
UChicago Medicine

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

Feat. J. Crombie
16:27
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Therapeutic Advances in T-Cell Lymphoma in 2024

Feat. S. Barta
33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
17:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

Feat. L. Sehn
14:17
SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

Feat. A. Zelenetz